An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

Next Previous
Trial Profile

An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CASTING
  • Sponsors Roche

    • Most Recent Events

    • 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Mar 2017 Planned End Date changed from 1 Dec 2020 to 18 Dec 2020.
    • 07 Mar 2017 Planned primary completion date changed from 1 Dec 2020 to 18 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top